Table 1.

Clinical features in 145 patients tested in this study

	VGKC-Ab ≥400 pM (n = 69)			VGKC-Ab <400 pM (n = 76)
	LE (n = 39)	NMT/MoS (n = 19/2)	Others^{^a} (n = 9)	LE (n = 20)	NMT/MoS (n = 14/0)	Others^{^a} (n = 42)
Age, y (range)	58 (6–82)	52 (1–78)	38 (1–70)	48 (21–82)	39 (21–85)	41 (3–84)
Male: female ratio	18:21	15:6	4:5	8:12	7:7	26:16
Memory loss	36	2	3	16	0	20
Confusion	35	2	4	18	0	23
Seizures^{^b}	28	1	4	12	0	17
Neuromyotonia^{^b}	2	20	1	0	14	5
MRI medial temporal high signal on T2 or FLAIR^{^b}	31	1	0	13	0	5
Hyponatremia^{^b}	20	1	0	5	0	6
Movement disorders^{^c}	8	1	2	1	0	7
Active tumor^{^b}	10	7	1	0	1	5
Any dysautonomia^{^d}	8	7	1	1	6	4
VGKC-Ab titer, pM (range)	895 (407–2493)	780 (426–2593)	561 (400–741)	49 (0–384)	93 (71–384)	13 (0–386)

The data represent the number or median (range).
↵^aFor a description of the patients in the Others category; see Materials and Methods.
↵^bData were available for 144 patients.
↵^cData were available for 124 patients.
↵^dData available for 130 patients.